SEC Form 4 · accession 0000899243-18-011951
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew S Boyer
Officer — Exec VP, Comm Optns
Period of report
May 4, 2018
Accepted (ET)
May 8, 2018 · 7:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | May 4, 2018 | A | 2,000 | — | A | 2,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2 | $15.01 | May 7, 2018 | A | 272,480 | A | — | May 7, 2028 | Class A Common Stock | 272,480 | 272,480 | D |
| Restricted Stock UnitsF3,F4 | — | May 7, 2018 | A | 66,622 | A | — | — | Class A Common Stock | 66,622 | 66,622 | D |
Explanation of responses
- F1Received in exchange for 2,000 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA").
- F2The option vests in four equal annual installments beginning on May 07, 2019.
- F3Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- F4The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.